Oral Contraceptives and Liver Injury
نویسندگان
چکیده
منابع مشابه
Oral contraceptives and liver function
SYNOPSIS Oral contraceptives can cause liver damage and jaundice but this is very rare in women in the United Kingdom. The drugs are contraindicated where there is a history of recurrent intrahepatic cholestasis of pregnancy and acute or chronic disturbance of liver function which can be congenital or acquired. It is not yet known whether the oestrogenic or progestogenic components of oral cont...
متن کاملOral contraceptives after liver disease.
Administration of oral contraceptives to 10 women was started two weeks after the normalization of the serum enzyme activities in the convalescent period of viral hepatitis, and to five women eight weeks after an operation of obstructive jaundice. Routine liver function tests were performed at intervals of two weeks for two to three months. The liver function tests stayed within normal limits d...
متن کاملOral Contraceptives Use and Liver Cancer Risk
Studies about the association between oral contraceptives use and liver cancer risk have generated controversial results. Therefore, a meta-analysis of cohort and case-control studies was performed to quantitatively summarize the existing evidence.Eligible studies were identified by a computer search of PubMed and Embase databases and handed-search of reference lists, without any limitations. S...
متن کاملLiver tumors and oral contraceptives: pathology and pathogenesis.
Since 1973, over 200 cases of liver masses associated with oral contraceptive usage have been reported. Nearly 100 have been liver cell adenomas and 11 have been hepatocellular carcinomas. Focal nodular hyperplasia (FNH) appears only coincidentally associated, but with a particular hemorrhagic tendency. Bile duct proliferation distinguishes FNH from liver cell adenoma. Two typical cases are pre...
متن کاملOral Contraceptives
Current low dose OCs are highly effective with an excellent safety profile and many associated health benefits No single product has been shown to be superior in efficacy, safety or tolerability There is no "one size fits all" OC; different women may require different formulations Smoking particularly after age 35 with concurrent OC use greatly increases cardiovascular and thrombotic risks Age ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1965
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.5451.1672